All News

Guidance for pharmacy technicians as they continue to learn and start their careers.

By improving health insurance coverage and cost of inhalers, such as out-of-pocket caps, access to care can be increased. Some companies are aiming to improve access by implementing price caps.

Mirikizumab met both co-primary end points and all secondary end points at week 52, according to results presented at Digestive Disease Week in Washington DC.

Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.

FKS518 (Fresenius Kabi) would be indicated for the treatment of osteoporosis in men and women, including glucocorticoid-induced osteoporosis and bone loss due to prostate or breast cancer.

Expert discusses the challenges faced by pharmacists in palliative and hospice care.

Tune into this special episode of “Public Health Matters” to hear Emma White, the founder and president of the nonprofit organization Life Is Worth It, discuss her mental health journey and how she used it to educate adolescents, teenagers, and young adults on mental wellness.

Emily Griffin discusses her career in pharmacy and in digital content creation.

The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.

Data show women with poor cardiovascular health may have an increased risk of early signs of cognitive decline in midlife.

For patients with a blood eosinophil count of 150 cells/µL or greater, tezepelumab had a significant reduction of approximately 37% in the rate of moderate or severe exacerbations.

Lisocabtagene maraleucel is being investigated for mantle cell lymphoma, relapsed or refractory (R/R) large B-cell lymphoma, and R/R follicular lymphoma.

Approximately 40% of caregivers make dosing errors when administering liquid medication to children.

Body mass index is the main driver of type 2 diabetes globally, accounting for 52.2% of disability-adjusted life years.

Pharmacists play a crucial role in managing pain for cancer patients in palliative care.

The panelists expressed concerns about clinical trial data and concluded that the benefits do not outweigh the risks, but the FDA does not have to follow their recommendation.

In addition to racial inequities in access to care, socioeconomic challenges are very common for the specialty medications necessary in MS.

The immunizing technicians stated they had greater job satisfaction and had a greater sense of being valuable pharmacy members

Compared with pembrolizumab alone, the combination treatment showed stronger recurrence-free survival and distant metastasis-free survival in patients with resected high-risk stage III or IV melanoma.

In prior studies, higher levels of physical activity were associated with higher prevalence of coronary artery calcium.

Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.

Adults who did not report past 3-day electronic nicotine delivery system use did not have an increased risk of asthma incidence.

Evidence indicates that up to 25% of all prescriptions for children could be dosed inappropriately, making it the most common type of medication administration error.

Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.

The study showed that belantamab mafodotin plus pomalidomide and dexamethasone (BPd) significantly improved progression-free survival compared to pomalidomide plus bortezomib and dexamethasone (PVd).

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV for lung cancer patients.

Asciminib demonstrated stronger efficacy, safety, and tolerability, as well as less adverse events in patients compared with those who received investigator-selected standard-of-care tyrosine kinase inhibitors.

Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.